Key Figures Q1 2004

Key Figures provide a succinct overview of the most significant developments for each period under review. You can view earlier quarters or years if you wish. Furthermore, you can find extensive reports by downloading press releases for the period of your choice.

Q1 2004 operating profit of EUR 110 million substantially higher than expected.

• Sales up 29% from Q1 2003, mainly because of contribution from DSM. Nutritional Products and autonomous volume growth of 5%.
• Operating profit 21% higher than in Q1 2003; net profit up 8% from Q1 2003.
• Development of DSM Nutritional Products above expectations.
• DSM Anti-Infectives puts results of Life Science Products under strong pressure.
• Q2 operating profit expected to be around Q1 2004 level; profit on ordinary activities after taxation for 2004 expected to be clearly higher than that for 2003.